Mexico Liver Diseases Therapeutics Market Report 2022 to 2030

Mexico Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Mexico Liver Disease Therapeutics market will reach a value of $550 Mn from $346 Mn in 2022, growing at a CAGR of 6 % during 2022-2030. Liver Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Liomont, Laboratorios Senosiain, and Silanes Laboratorios. The Liver Disease Therapeutics market in Mexico is segmented into different types of disease and different therapy types. Some of the major factors affecting the Mexico Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10MXPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Vishwa Modhia

Buy Now

Mexico Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Mexico Liver Disease Therapeutics market will reach a value of $550 Mn from $346 Mn in 2022, growing at a CAGR of 6 % during 2022-2030.

Mexico is an upper middle-income, developing country located in North America with a North Pacific Ocean, Gulf of Mexico, and Caribbean Sea coastline. In 2020, liver disease was the sixth leading cause of death in Mexico, accounting for more than 41,000 deaths per year, with a death rate of roughly 31 deaths per 100,000 inhabitants, which was three times greater than the rate seen in the United States.

According to the latest WHO data published in 2020 Liver Disease Deaths in Mexico reached 29,838 or 4.83% of total deaths. The age-adjusted Death Rate is 24.62 per 100,000 of population ranks Mexico 76^th in the world. Mexico's government spent 6.2% of its GDP on healthcare in 2020.

Mexico Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The alcoholic liver disease remains the leading cause of chronic liver disease in Mexico; however, non-alcoholic fatty liver disease (NAFLD) and its link to the obesity epidemic (in 2019, it was estimated that 72 % of adult Mexicans are overweight and 36 % are obese) and metabolic syndrome is rapidly becoming the leading cause of chronic liver disease, particularly among women. The development of appropriate detection programmes will result in an increase in the number of admissions to the CENATRA's LT waiting list. Mexico has a large population, is close to the American economy, and has low labour costs. These aspects could boost Mexico's Liver Disease Therapeutics market.

Market Restraints

Cirrhosis identification is one of Mexico's most pressing issues. Many patients go undiagnosed due to a lack of screening programmes. Access to healthcare services in Mexico is limited, particularly in rural and distant locations. This can lead to delayed liver disease detection and treatment, which can lead to more severe liver damage and consequences. Mexico has significant economic disparities, a high incidence of labour informality, and rising criminality. These factors may deter new entrants into the Mexico Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Laboratorios Liomont: Laboratorios Liomont is a Mexican pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Laboratorios Senosiain: Laboratorios Senosiain is a Mexican pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Silymarin and Glycyrrhizin
Sanfer: Sanfer is a Mexican pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Silanes Laboratorios: Silanes Laboratorios is a Mexican pharmaceutical company that produces a variety of therapeutics, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

In Mexico, the Federal Commission for Protection against Sanitary Risks (COFEPRIS) is responsible for regulating the registration and approval of drugs, including those used for liver disease treatment. COFEPRIS follows a regulatory framework that ensures the safety and efficacy of drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.